Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals ( REGN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 2.5%. By the end of trading, Regeneron Pharmaceuticals fell $8.87 (-3.2%) to $270.74 on average volume. Throughout the day, 1,104,322 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 812,700 shares. The stock ranged in price between $267.56-$281.72 after having opened the day at $279.70 as compared to the previous trading day's close of $279.61. Other companies within the Health Care sector that declined today were: Spherix ( SPEX), down 29.2%, Star Scientific ( STSI), down 23.0%, Cell Therapeutics ( CTIC), down 16.5% and Biocryst Pharmaceuticals ( BCRX), down 15.4%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $28.4 billion and is part of the drugs industry. The company has a P/E ratio of 40.8, above the S&P 500 P/E ratio of 17.7. Shares are up 1.6% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share.

On the positive front, ProPhase Labs ( PRPH), up 27.8%, Oramed Pharmaceuticals ( ORMP), up 21.9%, Mast Therapeutics ( MSTX), up 20.4% and Prana Biotechnology ( PRAN), up 7.8% , were all gainers within the health care sector with Teva Pharmaceutical Industries ( TEVA) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round